1. Scrip
  2. >>Business
  3. >>Earnings

AbbVie Gets Humira Erosion Right, But Skyrizi/Rinvoq Disappoint Investors

 
• By Joseph Haas

Humira’s US revenue declines by 26% as biosimilar adalimumab makes its debut. Follow-ons Skyrizi and Rinvoq post strong growth, but fall short of Street consensus estimates.

Sales decline
Humira suffered significant biosimilar erosion during Q1, but it was in line with projections • Source: Shutterstock

AbbVie Inc. reported that US sales erosion of top-seller Humira (adalimumab) due to domestic biosimilar competition is proceeding very close to expectations on 27 April, but analysts focused on Humira successors Rinvoq and Skyrizi posting quarterly sales numbers below consensus, although year-over-year growth remained strong.

On its first quarter sales and earnings call, AbbVie noted that Humira – now facing competition from Amgen, Inc.’s Amjevita, with multiple biosimilar versions of adalimumab set to launch later this year – saw a 26.1% year-over-year domestic sales decline during the quarter, still bringing in nearly $2.95bn

More from Earnings

BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

 
• By Alaric DeArment

The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

 
• By Mandy Jackson

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.

More from Business